Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8837432 | 0.82 | KMT2A (0.46) | KMT2AKDM4ECNR2MEN1CA12 | |
| SCHEMBL4491485 | 0.81 | KMT2A (0.61) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL14852 | 0.81 | KMT2A (0.61) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL3605081 | 0.81 | KMT2A (0.61) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL5314524 | 0.79 | KMT2A (0.59) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL14862123 | 0.79 | KMT2A (0.59) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL3599158 | 0.79 | KMT2A (0.59) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL22497546 | 0.79 | KMT2A (0.59) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL7230378 | 0.79 | KMT2A (0.65) | KMT2AKDM4EPOLBRECQLTSHR | |
| SCHEMBL552189 | 0.79 | KMT2A (0.59) | KMT2AKDM4EPOLBRECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2164833-A2 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009010139-A2 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | WO | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2164833-A2 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009010139-A2 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | WO | disclosed |
| EP-1179529-A1 | NOVEL HYDROXAMIC ACID DERIVATIVES | Daiichi Fine Chemical Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-1101492-A1 | NOVEL REMEDIES FOR ALLERGIC DISEASES | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | KMT2A 3779/4885KDM4E 3277/4885POLB 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.